Clinical Trial: A Phase I/IIa Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333469) titled 'A Phase I/IIa Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma' on Dec. 30, 2025.

Brief Summary: The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.

Study Start Date: Jan. 19

Study Type: INTERVENTIONAL

Condition: Solid Tumor and Lymphoma

Intervention: DRUG: HX111 for injection

HX111, 0.5-2.5mg/kg, once every 3 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hanx Biopharmaceuticals (Wuhan) C...